This article is more than 5 years old. Information may no longer be current.
Top takeaways from CMHC 2019
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top five news reports posted from the Cardiometabolic Health Congress, held from Oct. 10 to 13 in Chicago.
Healio.com/Endocrinology readers were interested in the potential of simultaneous combination therapy in treating type 2 diabetes, how to address high insulin prices, how technology is transforming diabetes management and more.
All content from the meeting is available under the Meeting News tab.
Simultaneous combination therapy shows major potential in type 2 diabetes
When treating patients with type 2 diabetes, physicians may have more success if they use simultaneous combination therapy immediately rather than following the traditional stepped-up method of waiting to intensify treatment.
Four strategies to obtain affordable insulin
As the cost for insulin continues to rise, clinicians can take several proactive steps to help uninsured and underinsured patients afford their medications today.
‘Digiceuticals,’ new CGM devices, HbA1c alternatives transform diabetes management
The growing abundance of technology options for better diabetes management and the trend away from HbA1c as the only evaluation metric for the condition are important parallel phenomena.
Icosapent ethyl appropriate to use to reduce CV risk, despite pending questions
Findings of cardiovascular benefit with icosapent ethyl treatment from the REDUCE-IT trial have already revealed actionable clinical implications, but determining whether triglyceride reductions or eicosapentaenoic acid increases are the key mechanisms will be the focus of continuing research.
Lifestyle changes as important as medication to prevent, treat type 2 diabetes
Intensive lifestyle interventions and metformin therapy have had significant success in treating type 2 diabetes and should both be considered when deciding on prevention and treatment.